Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25850207 | 0.77 | DNM1 (0.34) | CNR1CNR2 | |
| SCHEMBL26037626 | 0.75 | — | — | |
| SCHEMBL26050598 | 0.70 | — | — | |
| SCHEMBL24341855 | 0.69 | FAAH (0.44) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL25850206 | 0.68 | FAAH (0.43) | CNR1CNR2 | |
| SCHEMBL16377586 | 0.68 | EPHX2 (0.45) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL18897623 | 0.68 | EPHX2 (0.45) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL26035258 | 0.68 | CNR1 (0.38) | CNR1CNR2MEN1ALDH1A1MAPT | |
| SCHEMBL16377524 | 0.67 | SELP (0.47) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL21096814 | 0.67 | FAAH (0.46) | CNR1CNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CNR1 4510/4885CNR2 4584/4885MEN1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.